5. Allergan


Dublin, Ireland
2016 generic sales: $4.5 billion

Formerly Watson Pharmaceuticals and Actavis, Allergan rounded out the top five in this analysis of the top drugmakers for 2016. As industry-watchers know, the company offloaded its generics offerings to Teva during the period for this report, representing a major shakeup and the latest consolidation move for a sector facing painful price pressures.

In a move to reshape its focus, Allergan inked a deal to sell its generics assets to Teva back in 2015, with the deal closing in August last year. Separately, Allergan also pursued a megamerger with Pfizer last year, a move ultimately foiled by new rules from U.S. authorities.

Even though it’s out of the generics business now, the company was named as one of a group under investigation for alleged generics price collusion. Allergan is also the target in a shareholder lawsuit claiming execs hid behind-the-scenes pricing practices that put the company at risk.

RELATED: Surprised shareholders target Allergan over generics pricing probe

In the U.K., authorities have recently gone after Actavis for “excessive and unfair prices” on a generic in one case, and for “illegal” deals with Concordia in another. Both are now issues in the hands of India’s Intas, which picked up Actavis assets in the country from Teva.

5. Allergan

Suggested Articles

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.

Analysts are cautiously optimistic Amgen's $13.4 billion purchase of Celgene's psoriasis blockbuster Otezla will pay off.